I'm not sure what is worse;
a) the addition of another "drug candidate", despite spending over $70m dollars over 10 years and not achieving anything from the other 6 "candidates" still in this presentation.
b) allocating 3 whole pages to "in-house R&D", only a few months after announcing a pivot away from internal manufacturing;
Or
c) that the ASX even allowed this presentation to go out, despite the above, and with a sub $7m market cap, and over $2m p/quarter burn..
It's either delusional, or [insert only other possible reason].
Add to My Watchlist
What is My Watchlist?
